Biocon Group Ppt

Embed Size (px)

Text of Biocon Group Ppt

8lCCCn LlMl1Lu

Anjana GvaviaDhivva javavamanXiaovu Liang lndla's loremosL 8loLech Companv 8ACkC8Cunu 8locon was found ln november 29 Lh 1978 locused from enzvmes manufacLurlna Lo developmenL ofblopharmaceuLlcals lndla's flrsL bllllon dollar bloLech companv 1sL ln lndla and 20Lh ln world ln Lerms of revenue and markeLcaplLallzaLlon !olnL venLure beLween Leslle Auchlncloss and klran Mazumdar.MlLLS1CnLS 1978:8locon lndla colloboraLed wlLh8locon Chemlcals LLd. 1979: ManufacLure and exporL enzvmes LouSA and Lurope. 1989:unllever acqulred 8locon ChemlcalsLLd 1990: lafracLor Lechnoloav 1994: LsLabllshes Svnaene 1996: LnLered pharmaceuLlcals and sLaLlns. 1998: 8locon buvs unllever's shareholdlnaand became an lndependenL enLlLv. 2000: LsLabllshes Cllnaene 2001: uS luA approval for manufacLure ofLovasLaLln. 2003: llrsL companv Lo develop humanlnsulln on a lchla expresslon svsLem. 2006: Launches lndla's flrsL anLlcancer drua8loMab.8lCCCn Anu l1S Su8SlulA8lLSCLC- klran M Shaw 1933- 8orn ln lndla 1973- 8.Sc ln Zooloav 1973-MasLer brewer from8allard unlverslLv lnMelbourne SLarLed from her aaraaewlLh lnlLlal caplLal of $200urua ulscoverv lpellnelnLellecLual roperLv 8locon LlmlLed flled 23 new paLenLs ln Lhe flrsL-quarLer of2008, Laklna Lhe LoLal Lo 881 flled, of whlch 134 werearanLed paLenLs 1he l aeneraLed ls elLher shared or owned bv 8locon Lx: Cral lnsulln paLenL ls shared bv nobex, a small uScompanv and 8locon. Lx: AnLlbodles for lmmunoLherapv based cancer LreaLmenL-aLenL shared bv vacclnex lnc of newvork and bloconaLenL for lnSuCLnaLenL for A1C8vAS1A1lnSCIENCE AND TECHNOLOGYBYDHIVYA JAYARAMANlnsuaen1M 8locon ls Lhe flrsL companv, aloballv Lo manufacLure humanlnsulln lnSuCLn, uslna a expresslon svsLem, 2004. 8locon's lnsulln ls produced bv unA recomblnanL Lechnoloavuslna a veasL, lchla pasLorls. lnSuCLn ls Lhe world's flrsL recomblnanL human (r-unA)lnsulln 1he human lnsulln faclllLv also supporLs oLher producLs ln8locon's research plpellne such as ln-103, Lhe novel lnsullncon[uaaLe for oral dellverv.lnsuaen1M lnsulln ls a hormone secreLed bv Lhe beLa cells of lsleL oflanaerhans wlLhln Lhe pancreas. lL reaulaLes Lhe use and sLoraae of food, parLlcularlvcarbohvdraLes. ln Lhe absence of lnsulln (or low), alucose ls noL Laken up bvmosL bodv cells and Lhe bodv bealns Lo use faL as an eneravsource (le, Lransfer of llplds from adlpose Llssue Lo Lhe llverfor moblllzaLlon as an enerav source)ulabeLes ulabeLes ls a dlsease ln whlch Lhe bodv does noL produce orproperlv use lnsulln.Ma[or 1ypes of D|abetes 1vpe 1-8esulLs from Lhe bodv's fallure Lo produce 1vpe 2-8esulLs from lnsulln reslsLance (a condlLlon ln whlchLhe bodv falls Lo properlv use lnsulln), comblned wlLh relaLlvelnsulln deflclencv. CesLaLlonal ulabeLes-lmmedlaLelv afLer preanancv, 3 Lo10 of women wlLh aesLaLlonal dlabeLes are found Lo havedlabeLes, usuallv, Lvpe 2. re-dlabeLes ls a condlLlon LhaL occurs when a person's bloodalucose levels are hlaher Lhan normal buL noL hlah enouahfor a dlaanosls of Lvpe 2 dlabeLes.

lloctootloos lo Jlobetlc petsoo's blooJ olocose levels. compoteJwltb beoltbv loJlvlJools.Source: Plllson,8. - ulabeLes: A bevond baslcs aulde, pa.16 Causes of ulabeLes 1vpe 1 dlabeLes - Lhe cells ln Lhe pancreas LhaL make lnsullnare desLroved, causlna a severe lack of lnsulln. lnfecLlon wlLh a speclflc vlrus or bacLerla exposure Lo food-borne chemlcal Loxlns 1vpe 2 dlabeLes Lhere ls lnsufflclenL lnsulln avallable Lhe lnsulln LhaL ls avallable mav be abnormal and Lhereforedoesn'L work properlv lncreaslna aae CbeslLv hvslcal lnacLlvlLv PeredlLvSvmpLoms ulabeLes ofLen aoes undlaanosed because manv of lLs svmpLomsseem so harmless. Powever earlv deLecLlon of dlabeLessvmpLoms and LreaLmenL can decrease Lhe chance of developlnaLhe compllcaLlons of Lhe dlsease lrequenL urlnaLlon unquenchable 1hlrsL Loslna WelahL WlLhouL 1rvlna Weakness and laLlaue 1lnallna or numbness ln ?our Pands, Leas or leeL 8lurred vlslon Skln LhaL ls drv or lLchv lrequenL lnfecLlons or cuLs and brulses LhaL Lake a lona Llme Lohealulaanosls 1he deslred blood Clucose ls 70ma/dl 1he fasLlna blood Clucose LesL ls preferred for dlaanoslnadlabeLes ln chlldren and non preananL adulLs.Cral alucose Lolerance LesL and CesLaLlonal dlabeLesliip:]]video.google.com]videoplay?docid=6==iSo((i=o(i8ei=PicpSemKI(WiqgKbyPnnBg8q=diabeies8ll=en8ecomblnanL lnsulln5ootce. Novo - NotJlsk ptomotloool btocbote.po 6.8ecomblnanL lnsulln lnsulln ls a small, slmple proLeln. lL conslsLs of 31 amlno acld,30 of whlch consLlLuLe one polvpepLlde chaln, and 21 ofwhlch comprlse a second chaln. 1he Lwo chalns are llnked bva dlsulflde bond. 1he aeneLlc code for lnsulln ls found ln Lhe unA aL Lhe Lop ofLhe shorL arm of Lhe elevenLh chromosome. 1he double sLrand of Lhe elevenLh chromosome of unAdlvldes ln Lwo, exposlna unpalred nlLroaen bases whlch arespeclflc Lo lnsulln producLlon uslna one of Lhe exposed unA sLrands as a LemplaLe,messenaer 8nA forms ln Lhe process of LranscrlpLlon 1he m8nA sLrand carrles Lhe aeneLlc lnformaLlon perLalnlna Lolnsulln, from Lhe nucleus lnLo Lhe cvLoplasm, where lL aLLachesLo a rlbosome. 1he base sequence of Lhe m8nA Lhen LranslaLe lnLo an amlnoacld sequence whlch llnk LoaeLher Lo form speclflc proLelnssuch as lnsulln. 1he lnsulln ls Lhen lnLroduced lnLo Lhe lchla Lxpresslon - aveasL expresslon svsLem LhaL secreLes pro-lnsulln ln an exLra-cellular manner and Lherebv enables an eleaanL purlflcaLlonprocess for lnsulln.lnsuaen1MlermenLaLlon of veasL ln Lhe presence of alcohol

Cells are harvesLed bv conLlnuous cenLrlfuae

8loconverslon

Plah pressure chromaLoaraphv Lo remove lmpurlLles

1he enLlre process ls laraelv auLomaLed and monlLoredconLlnuouslv ln a cenLral conLrol room.Mechanlsm of AcLlon lnsulln opens Lhe cell recepLors for alucose molecules LoenLer whlch ln Lurn ls uLlllzed ln Lhe form of enerav (A1) Locarrv ouL Lhe varlous acLlvlLles bv Lhe bodv. lL sLarLs lLs acLlon afLer 30 mlns of ln[ecLlon and aLLalns peakafLer 2 hrs, remalnlna ln Lhe bodv for up Lo 6-8 hrs.lndlcaLlons: All Lvpes of dlabeLes melllLus. lor qulck acLlon and fasLer peak of lnsulln. 1aken as subcuLaneous ln[ecLlon. Also used ln Lhe lCus and wards as lv (lnLravenous).uosaae forms IN5UGLN kComposlLlon:Soluble/ 8eaular lnsulln - 10ml vlals of 40lu/ml sLrenaLh IN5UGLN NComposlLlon:lsophane (nP) lnsulln - 10ml vlals of 40lu/ml sLrenaLh IN5UGLN 30/70ComposlLlon:lnsulln blphaslc, 30 Soluble and 70 nP - 10ml vlals of 40lu/mlsLrenaLh. IN5UGLN 50/50ComposlLlon:30 soluble and 30 nP - 10ml vlals of 40lu/ml sLrenaLhAdmlnlsLraLlon of lnsuaen ln[ecLlon alds lnsulln pens lnsulln [eL ln[ecLors SubcuLaneous lnfuslon seLs LxLernal lnsulln pumpsln-103 (Cral lnsulln) WhaL?8locon ls developlna ln-103 - a con[uaaLed lnsulln molecule LhaL lsorallv dellvered and LaraeLed Lowards Lhe LreaLmenL of dlabeLes. Whv?SubcuLaneous lnsulln ls verv effecLlve ln Lhe LreaLmenL of dlabeLesbuL lLs prescrlpLlon ls aenerallv delaved due Lo lnconvenlence ofneedle usaae and poLenLlal hvpoalvcemla (caused bv excesslnsullnlsaLlon). Pow?Cral lnsulln (le. lnsulln ln LableL form) ls slmple and palnless LoadmlnlsLer. lL ls dellvered Lhrouah Lhe porLal veln, mlmlcklna LhenaLural phvsloloav of Lhe bodv. When?hase l Lrlal ls compleLed and Lhere ls an onaolna hase ll Lrlal. uaLafrom Lhls sLudv was presenLed aL LASu, 8ome ln SepLember, 2008.ln-103 (Cral lnsulln)FINANCECvervlew of llnanclal SLrenaLh 8locon LlmlLed serves parLners and cusLomers ln over 30 counLrles lL ranks flrsL ln Asla's 8loLech lndusLrv ln Lerms of markeLcaplLallzaLlon. 8locon LlmlLed had lLs lnlLlal ubllc Cfferlna (lC) ln 2004 Second lndlan companv Lo cross a markeL caplLallzaLlon of18llllon uS dollars on Lhe flrsL dav of llsLlna.8locon's llnances sLem from ma[or areas: - 8lopharmaceuLlcal roducLs - such as branded and aenerlcdruas, Als 8locon LlmlLed wenL publlc wlLh lLs lnlLlal ubllc Cfferlna (lC)ln 2004 and achleved a markeL cap of over 18llllon uS dollarson Lhe flrsL dav of llsLlna CusLom 8esearch Servlces - ln Lhe areas of precllnlcal andcllnlcal research ManufacLurlna and MarkeLlna+25% $.1 +10% $.3 20. Biocon (India)NA ($.1) +25% $.3 19. Nektar Therapeutics (U.S.)100% ($.1) +55% $.3 18. Crucell (Netherlands)>999% $.1 +51% $.3 17. Cubist Pharmaceuticals (U.S.)NA (>$.1) +84% $.3 16. Abraxis Bioscience (U.S.)>999% $.1 +41% $.3 15. OSI Pharmaceuticals (U.S.)NA >$.1 +9% $.5 14. Millenium Pharmaceuticals (U.S.)(>999%) >$.1 (13%) $.6 13. ImClone Systems (U.S.)(65%) ($.4) +36% $.8 12. Elan (Ireland)+3% ($.2) +53% $.8 11. Amylin Pharmaceuticals (U.S.)(49%) $.1 +39% $1.1 10.Actelion (Switzerland)+128% $.2 +56% $1.4 9. Celgene (U.S.)(>999%) ($.2) +1% $1.8 8. Cephalon (U.S.)+359% $.5 +14% $2.8 7. CSL ( Australia)+193% $.6 +18% $3.2 6. Biogen Idec (U.S.)>999% $.5 +20% $3.8 5. Genzyme (U.S.)>999% $1.6 +40% $4.2 4. Gilead Sciences (U.S.)(56%) $.2 +42% $5.0 3. UCB (Belgium)+31% $2.8 +26% $11.7 2. Genentech (U.S.)+7% $3.2 +4% $14.8 1. Amgen (U.S.)% Growth 2007 Income(billions)% Growth 2007 Revenue(billions)Company/CountryLead|ng 8|otech Compan|es 2007 - 8y kevenue and Income 8|ocon | Conso||dated I|nanc|a| erformance: rof|t and Loss data93.8 40.3 35 40 28 Net Profit48.2 - - - - Exceptional Item, Net45.4 40.3 35 40 28 Profit From Operations13 17 31 18 23 Income Tax48 43.8 41.3 43.6 32.7 Profit Before Tax172 156 118.6 104.6 76.6 Total19 13.5 5.8 4.4 3.2 Depreciation2 1.8 0.4 0.4 0.4 Interest and Finance Charges151 140.6 112.4 98.4 73 Manufacturing & Other ExpensesExpenditure220 200 160 147 110 Total Revenues7.2 0.8 1 3 0.2 Other Income212.6 198.8 159 143.3 109.8 Total44.4 32.8 20 13.3 7.8 Contract Research and Technical Licensing Fees9.2 19 17 18 14 Enzymes159 147 122 112 88 Bio PharmaceuticalsSales2008 2007 2006 2005 2004 In Thousand USD ($ 1000)Summarv of 8alance sheeLSnapshoL of flnance